HomeProductsPeptidesSermorelin 2mg

Sermorelin 2mg

1 Vial $37.99 ($37.99)
Sale Most Popular!
2 Vials $75.98 $64.99
Save $10.99 ($64.99)
Sale Best Choice!
3 Vials $113.97 $92.99
Save $20.98 ($92.99)
1 Vial
2 Vials
3 Vials
4 Vials
5 Vials
10 Vials
20 Vials
40 Vials
100 Vials
Grand total

Availability: Ships today if ordered and paid by 7AM EST

Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue used clinically to assess growth hormone secretion. It is of interest to researchers for its ability to improve bone density, reduce scaring, fight the effects of dementia, and reduce seizure activity.
Where to buy Sermorelin 2mg? Shop now for Sermorelin 2mg with exceptional quality and get more for less with our bulk sales. Quick 48-hour delivery available.


    3rd party checkout COA cust serv Purity shipping

    Sermorelin 2mg Properties

    Chemical Formula: C149H246N44O42S

    Molecular Mass: 3357.9

    Synonyms: UNII-89243S03TE, 89243S03TE, Sermoreline, Sermorelinum, Growth Hormone Releasing Factor (GRF) (1-29) amide

    CAS Number:  86168-78-7

    PubChem: 16132413

    Total Amount of the Active Ingredient: 2 mg (1 vial)

    Shelf Life: 36 months

    Product Quality

    Lab tests are occasionally published on the website.

    You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following:

    Cost of HPLC test

    Total amount of the order + shipping fee

    Peer-Reviewed Studies 

    A potentially effective drug for patients with recurrent glioma: sermorelin.

    Background: Treatment insensitivity is the main cause of glioma. This study was designed to screen out effective drugs for recurrent gliomas based on the transcriptomics data.

    Methods: A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study. There were 325 patients in the discovery cohort, including 229 primary patients and 92 recurrent patients. There were 693 patients in the validation cohort, including 422 primary patients and 271 relapsed patients. Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening. The analysis and drawing in this study were mainly based on R language.

    Results: After high-throughput drug screening, we found that recurrent glioma patients were most sensitive to sermorelin. Further analysis revealed that sermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status. GO and KEGG analyses found that sermorelin may inhibit tumor cell proliferation by cell cycle blocking. Moreover, sermorelin was also related to the immune system process and negatively regulated immune checkpoints and M0 macrophages. Lastly, the Kaplan-Meier method showed the patient’s benefit from sermorelin was independent of postoperative adjuvant treatment.

    Conclusions: Recurrent glioma patients are sensitive to sermorelin and it makes effect through glioma cells proliferation inhibiting and immune response enhancing.

    Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.

    White laboratory male rats, inbred male C57BL/6 and Balb/c mice, and male Wistar rats, all previously divided on the basis of the type of emotional reactivity, were used to compare the effects of ten peptide compounds of the tuftsin family and Selank on the behavioral manifestations of emotional stress created by a conflict situation. Peptides were shown to have positive emotional effects and antistress actions. Individual physiologically significant effects were seen, due to the molecular structures of the study peptides and/or their degradation fragments. The results demonstrate the potential for the synthesis of peptide compounds with predictable directions of pharmacological actions and safe for wide use.

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

    Sermorelin, a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with full biological activity of GHRH. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary. Hormone responses to intravenous sermorelin 1 microg/kg bodyweight appear to be a rapid and relatively specific test for the diagnosis of growth hormone deficiency. False positive growth hormone responses are observed in fewer children without growth hormone deficiency after sermorelin than after other provocative tests. Adult data indicate that the combination of intravenous sermorelin and arginine is a more specific test and this merits evaluation in children with growth hormone deficiency. However, normal growth hormone responses to intravenous sermorelin cannot exclude growth hormone deficiency due to a hypothalamic deficit: subnormal growth hormone response to other provocative tests is needed to confirm the presence of disease in these patients. Limited data indicate that once daily subcutaneous sermorelin 30 microg/kg bodyweight given at bedtime is effective in treating some prepubertal children with idiopathic growth hormone deficiency. Significant increases in height velocity were sustained during 12 months’ treatment with sermorelin and data in a few children suggest the effect is maintained for 36 months of continued treatment. Sermorelin induced catch-up growth in the majority of growth hormone-deficient children. Slow growing, shorter children with delayed bone and height age appear to have a good response to treatment with sermorelin. The effect of long term treatment with once daily subcutaneous sermorelin 30 microg/kg bodyweight on final adult height is yet to be determined. The effects of the recommended dosage of sermorelin have not been directly compared with those of somatropin. However, increases in height velocity from baseline values with subcutaneous sermorelin 30 microg/kg bodyweight per day, given as continuous infusion or as 3 divided doses, were less than those in children receiving once daily subcutaneous somatropin 30 microg/kg bodyweight. Intravenous single dose and repeated once daily subcutaneous doses of sermorelin are well tolerated. Transient facial flushing and pain at injection site were the most commonly reported adverse events.

    Conclusions: Sermorelin is a well tolerated analogue of GHRH which is suitable for use as a provocative test of growth hormone deficiency when given as a single intravenous 1 microg/kg bodyweight dose in conjunction with conventional tests. Limited data suggest that once daily subcutaneous sermorelin 30 microg/kg bodyweight is effective in promoting growth in some prepubertal children with idiopathic growth hormone deficiency.




    If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.


    The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider.

    In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.

    Note: In some cases wherein the assigned top colors are out of stock, a different top color will be used to ensure that your order will not be delayed. Should you need assistance identifying the peptide vial that you received, please send us an email at [email protected].


    The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat and/or cure any medical condition, ailment or disease. Bodily introduction of any kind into animals or human is strictly prohibited by law.


    How Many Vials?

    1 Vial, 2 Vials, 3 Vials, 4 Vials, 5 Vials, 10 Vials, 20 Vials, 40 Vials, 100 Vials


    Sermorelin 2mg Vials  

    How to reconstitute Sermorelin 2mg vials?

    Sermorelin 2mg vials contain a peptide powder, which is typically a puck or loose bits due to shipping. To reconstitute a Sermorelin 2mg vials, researchers typically use bacteriostatic water, combining it with the peptide powder according to the specific requirements of their research protocols.


    How to dose Sermorelin 2mg?

    The dosing of Sermorelin 2mg in vials form will vary according to the experiment being conducted. We do not provide dosage recommendations as our products are intended for research purposes only.


    How to administer Sermorelin 2mg?

    There are multiple methods of administering research products that are under investigation in various studies. The choice of administration technique should align with the specific goals and design of the researcher’s study. We provide products solely for research use, we do not offer advice on administration methods.